Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

nÃo hà / Introdução: O cÃncer Ãum dos principais problemas mundiais de saÃde e uma das causas mais importantes de morbidade e mortalidade em saÃde pÃblica. Segundo a OrganizaÃÃo Mundial de SaÃde (OMS) Ãa segunda causa de morte no mundo;perdendo apenas para as doenÃas cardiovasculares.Temos alta incidÃncia nacional de pacientes com cÃncer de pulmÃo avanÃado. Hà imprevisibilidade de perfis epidemiolÃgicos e respostas terapÃuticas. A biologia molecular tem sido importante na caracterizaÃÃo sobre a diferenciaÃÃo tumoral e prognÃstico da doenÃa.Novos tratamentos sÃo direcionados por caracterÃsticas farmacogenÃmicas. Pouco se sabe sobre a prevalÃncia desses genes no CearÃe na AmÃrica Latina, bem como sobre caracterÃsticas clÃnicas e desfechos relacionados. Objetivo: Identificar as caracterÃsticas e distribuiÃÃo do perfil epidemiolÃgico dos pacientes portadores de neoplasia de pulmÃo avanÃado, atendidos no ambulatÃrio de oncologia do Hospital de Messejana - Dr. Carlos Alberto Studart. Material e Métodos: Estudo observacional, prospectivo e analítico com inclusão de 135 pacientes portadores de neoplasia de pulmÃo avanÃado, entre 08/2012 a 12/2014; sendo analisados quanto a distribuiÃÃo de frequÃncia por procedÃncia, sexo, raÃa, escolaridade, queixas clinicas, tabagismo e perfil molecular. Resultados: Houve predominÃncia na procedÃncia de pacientes oriundos de cidades do interior do Cearà (69%); pacientes do sexo feminino (51,1%), baixa escolaridade (1o grau ou menos -19%), agricultores (22,4%), Pardos (47,4%) e tabagistas.(79%)O subtipo histolÃgico adenocarcinoma foi predominante (32,5%). DispnÃia foi a principal queixa clinica. O atendimento inicial predominante se deu no perÃodo de internamento (75,5%). Conclusão: Neste grupo de pacientes identificou-se um perfil de caracterÃsticas epidemiolÃgicas prÃprias. Criou-se um registro de cÃncer do hospital.Hà proporcionalidade de resultados com a literatura. / Introduction: Cancer is a leading global health problems and one of the most important causes of morbidity and mortality in public health. According to the World Health Organization (WHO) is the second leading cause of death worldwide, second only to the diseases cardiovasculares.Temos national high incidence of patients with advanced lung cancer. There unpredictability of epidemiological profiles and therapeutic responses. Molecular biology has been important in the characterization of tumor differentiation and prognosis of the disease. New treatments are directed by pharmacogenomic characteristics. Little is known about the prevalence of these genes in CearÃand Latin America as well as on clinical characteristics and outcomes related. Objective: To identify the characteristics and distribution of the epidemiological profile of patients with advanced lung cancer, treated at the oncology clinic at the Messejana Hospital - Dr. Carlos Alberto Studart. Material and Methods: An observational, prospective and analytical study with inclusion of 135 patients with advanced lung cancer, between 08/2012 to 12/2014; being analyzed for the distribution of origin by frequency, sex, race, education, clinical complaints, smoking and molecular profile. Results: There was a predominance in the success of patients from small towns of CearÃ(69%); female patients (51.1%), low education (first degree or less -19%), farmers (22.4%), Pardos (47.4%) and smokers. (79%) The histological subtype was adenocarcinoma predominantly (32.5%). Dyspnea was the main complaint clinica.O predominant initial treatment occurred in hospital stay (75.5%). Conclusion: In this group of patients identified a profile of epidemiological characteristics. Created a hospital cancer registry. There proportionality results with the literature.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of Master of Medicine in the branch of Internal Medicine / Medical Oncology. Johannesburg 1st September 2014 / Introduction: Tyrosine kinase inhibitors and EGFR mutations has changed the treatment approach to lung cancer globally. This retrospective study will look at factors associated with EGFR mutations and define the EGFR mutation rate in South Africa. Methods: Retrospective record review from NSCLC patients in South Africa who were tested for EGFR mutations at Lancet Laboratories during 1st September 2009 to 30th June 2012. Chi-squared test was used to determine association with categorical variables. Kaplan- Meier survival analysis was done for OS and PFS between EGFR mutation positive and negative patients. Cox proportional hazards were used for subgroup analysis. Treatment practices and response were described. Results: 170 lung cancer samples were evaluable for EGFR mutation and 37 were EGFR mutation positive (21.8%). There were 22 (59.5%) exon 19 deletions, 11 (29.7%) L858R mutations, two G719X mutations, one S768I mutation and one exon 20 insertion. The median age was 63 (range 27-85). There were more females (55.6%) than males (44.4%) sent for mutation testing. Most patients were whites (71%), followed by blacks (18.3%), and other race (10.7%). 85% of all NSCLC samples tested were adenocarcinoma. None of the squamous cell carcinoma tested was positive for EGFR mutation. Smoking status was inversely proportional to EGFR mutation status (p<0.001). Over 60% patients received chemotherapy first and second line and responses decreased with each line of chemotherapy. Median PFS and OS were not different between the EGFR mutation positive and negative groups (6.85 versus 6.8 months; HR 1.6; 95% CI 0.70-3.65; p=0.2543 and 11.5 versus 12.9 months; HR 0.70; 95% CI 0.28-1.75; p=0.44, respectively). On multivariate analysis, only non-white race was associated with decrease in OS (HR 6.66; 95% CI 2.31-19.19; p=0.0004). Conclusion: EGFR mutation rate in South African lung cancer patients was 21.8%. 89% of all EGFR mutations were either exon 19 deletions or L858R point mutations. Most EGFR mutations were associated with adenocarcinoma of the lung in non-smokers. These findings were consistent with current literature in western countries. Treatment practice remained chemotherapy based, with few patients receiving EGFR TKIs. Efforts should be made to prioritized targeted treatment approach in lung cancer in South Africa.

Stereotactic Body Radiation Therapy (SBRT) is a modern precision radiation therapy to deliver the dose in 1 to 5 fractions with high target dose conformity, and steep dose gradient towards healthy tissues. The dose delivered is influenced by the leaf width of the MLC, especially in case of SBRT. Treatment plans with high definition (HD) MLC having leaf-width 2.5 mm and normal MLC having leaf-width 5 mm, were compared to quantify dosimetric and radiobiological parameters. Dosimetric parameters conformity indices (CI), gradient indices (GI) and heterogeneity indices (HI) were compared. The radiobiological parameters were evaluated by normal tissue complication probability (NTCP) and tumor control probability (TCP) based on the equivalent uniform dose (EUD). The results show that there is dosimetric and radiobiological merit of the HD MLC over the normal MLC. However, the improvement is not consistent with all the plans and thus further research is required prior to conclusion. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2018. / FAU Electronic Theses and Dissertations Collection

Thesis (M.S.)--University of Alabama at Birmingham, 2009. / Title from PDF title page (viewed on Feb. 2, 2009). Includes bibliographical references (p. 35-48).

Licentiatavhandling (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 2 uppsatser.

Diss. (sammanfattning) Göteborg : Göteborgs universitet, 2007. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Thesis (doctoral)--Rijksuniversiteit te Utrecht, 1981. / Summary in Dutch. Includes bibliographical references (p. 65-72).